A novel treatment has demonstrated complete tumour regression in a preclinical model for Glioblastoma (GBM), an aggressive brain cancer. Researchers utilized a model that closely mimicked GBM growth in the human brain, achieving tumour elimination in the majority of cases without observed toxicity or recurrence.
The therapy employs Synthetic Super-Enhancers (SSEs) designed to target tumour cells by hijacking GBM stem cells' own gene control systems. Following a single administration, the treatment eradicated tumours in 83% of cases. Over an 11-month observation period, no recurrence or toxicity was reported. Furthermore, subsequent re-challenge tests detected no tumour formation, suggesting the development of a lasting protective effect.
The research team employed a dual-mechanism gene therapy, simultaneously delivering a cytotoxic agent to destroy tumour cells and immune-stimulating factors to activate the immune system. This combined strategy may function as an in-situ vaccine, educating the immune system to recognize cancer cells and generate immunological memory to prevent future recurrence.
Selective targeting was further validated using fresh tissue samples from GBM patients, confirming that healthy brain cells were spared while the SSE mechanism was exclusively expressed in tumour cells. Researchers emphasized the critical importance of minimizing damage to surrounding healthy tissue in GBM therapy. They are optimistic about advancing this approach to early-phase clinical trials to assess its safety and efficacy in humans.